Search - tctmd.com

Displaying 161 - 180 of 221

Sort: Relevancy | Date

News Daily News

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

Caitlin E. Cox

December 24, 2019

News Daily News

SILVER-AMI Bests GRACE for Predicting 6-Month Mortality After Acute MI in Elderly

L.A. McKeown

December 10, 2019

News Conference News HRS 2019

Grapefruit Juice Prolongs QT Interval, but How Much Does It Matter?

Todd Neale

May 13, 2019

News Daily News

Poor Diet Responsible for 11 Million Deaths Annually, With CVD a Leading Cause

Michael O'Riordan

April 04, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Todd Neale

February 07, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

L.A. McKeown

January 10, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

L.A. McKeown

December 21, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Caitlin E. Cox

January 08, 2018

News Industry News

Baim Institute Names Dr. C. Michael Gibson As CEO

December 05, 2017

Advertisement

Extreme Alcohol Intake Directly Damages the Heart, Study Confirms

SILVER-AMI Bests GRACE for Predicting 6-Month Mortality After Acute MI in Elderly

Grapefruit Juice Prolongs QT Interval, but How Much Does It Matter?

Poor Diet Responsible for 11 Million Deaths Annually, With CVD a Leading Cause

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Data Hint at Unintended Consequences of Hospital Readmissions Reduction Program

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Ticagrelor: Better Platelet Blockade Post-TAVR?

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Baim Institute Names Dr. C. Michael Gibson As CEO

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content